Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.
about
Biologic agents in juvenile spondyloarthropathiesTreatment of juvenile idiopathic arthritis: a revolution in careWhat does an adult rheumatologist need to know about juvenile idiopathic arthritis?Juvenile Idiopathic Arthritis: Diagnosis and TreatmentPredictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of ChildrDevelopment and retrospective validation of the juvenile spondyloarthritis disease activity indexEtanercept biosimilarsThe development and assessment of biological treatments for children.Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis.Clinical utility of etanercept in the treatment of arthritides in children and adolescents.Etanercept: a review of its use in autoimmune inflammatory diseases.Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?Judicious use of biologicals in juvenile idiopathic arthritis.Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.Enthesitis-related arthritis.Biologic-associated infections in pediatric rheumatology.Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.Safety and effectiveness of etanercept for treatment of juvenile idiopathic arthritis: Results from a postmarketing surveillance.Management of Juvenile Idiopathic Arthritis: A Clinical Guide.[Evidence of treatment of chronic inflammation in childhood and adolescence with biologics].Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis.Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.Risk, Timing and Predictors of Disease Flare after Discontinuation of Anti-Tumor Necrosis Factor (TNF) Therapy in Children with Polyarticular Forms of Juvenile Idiopathic Arthritis (JIA) in Clinical Inactive Disease.Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre.Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.
P2860
Q26766263-949196FF-3CA0-40B6-B6DE-049C6426A4ABQ26849497-E55EB404-3D90-4085-B4A3-10BC8C3E6D1FQ26995394-952825F5-BC4A-448E-807A-7B64E029080EQ28079246-5B0E572C-FBDC-4F54-9340-613CC18EA39CQ33801499-1BCBE776-083F-4E3F-A2D0-65E5E49A00A9Q34576920-400ECD11-30B9-44BF-892E-E6860C679547Q35020358-70F3D4E4-ADDE-4E57-BD7F-A4BF4E8DE4A6Q35135936-5FF32603-5CF8-4FA9-85EC-F0B9E8306716Q37313894-AB475B44-FFD9-48D4-9625-8AA6552779BFQ37325983-01E46C5C-FFAE-479E-8B63-540A99CE4917Q37676020-7B8FC1C1-025F-4CAA-93A5-3EEC5C297F17Q38230740-9AB1E301-5749-4A59-8A77-407B980EF30CQ38238947-1245F059-4421-4046-ACE9-DD9568AC8795Q38248905-572EFAAA-6F3D-4967-BF37-D5891F89434EQ38530469-C8E08CEE-BF77-4F40-A7E7-949CB3D6CFFBQ38559051-45EF32DE-A12B-4AFB-AE59-868152B2293DQ38589392-91C4C1B5-E0D2-4757-A6FB-DD03D9DB8CBDQ38711172-663D333F-3905-40BB-8A68-9A2290A2219AQ38817268-C0388CEE-23D1-4C3C-AD9B-64E2A72DC749Q38916421-3380081B-63B4-4131-8BEA-73C76669EF9EQ40179129-D0D71AA1-8609-4E3F-A841-E3DDAAC618B0Q40995768-1352B14A-9033-4467-9628-5388328D4BF7Q41311218-DA9DCCA7-30BC-410C-8D4A-4E5CDBF405D3Q47111826-C8C1E07E-7157-4E01-BAAF-8887278E0711Q50062242-701BA065-CD5D-4832-98C2-6D1D13BF54BBQ51425096-E45F3B39-46EC-482C-AFC4-B33D7391FAABQ52617055-EF56CBD5-E6F0-4207-8FDA-B75B0F2ED553Q54243353-08AE820E-6BC9-4BC1-8FEB-CD2DEA0E7685Q55617607-F5D32191-E850-4D62-8448-32E7981E370C
P2860
Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Efficacy and safety of open-la ...... week 12) of the CLIPPER study.
@ast
Efficacy and safety of open-la ...... week 12) of the CLIPPER study.
@en
type
label
Efficacy and safety of open-la ...... week 12) of the CLIPPER study.
@ast
Efficacy and safety of open-la ...... week 12) of the CLIPPER study.
@en
prefLabel
Efficacy and safety of open-la ...... week 12) of the CLIPPER study.
@ast
Efficacy and safety of open-la ...... week 12) of the CLIPPER study.
@en
P2093
P2860
P50
P1476
Efficacy and safety of open-la ...... week 12) of the CLIPPER study.
@en
P2093
Alberto Martini
Bonnie Vlahos
Chantal Job-Deslandre
Chuanbo Zang
Daniel Alvarez
Deborah Woodworth
Gerd Horneff
Gordana Susic
Ingrida Rumba-Rozenfelde
Ivan Foeldvari
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-203046
P407
P577
2013-05-21T00:00:00Z